Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.44 |
| ▸ | CTSD | P07339 | 7/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281124 | 0.95 | BACE1 (0.48) | BACE1CTSDADAM17MEN1NPC1 | |
| SCHEMBL3395251 | 0.95 | BACE1 (0.48) | BACE1CTSDADAM17MEN1NPC1 | |
| Formic Acid SCHEMBL13685480 | 0.86 | BACE1 (0.58) | BACE1CTSD | |
| SCHEMBL2279259 | 0.83 | ADAM17 (0.39) | ADAM17MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2281460 | 0.82 | BACE1 (0.37) | BACE1CTSDADAM17MEN1NPC1 | |
| Formic Acid SCHEMBL2282200 | 0.80 | BACE1 (0.60) | BACE1CTSD | |
| Formic Acid SCHEMBL2285120 | 0.80 | BACE1 (0.43) | BACE1CTSDNPC1MAPT | |
| SCHEMBL2277408 | 0.80 | BACE1 (0.64) | BACE1CTSD | |
| SCHEMBL2277405 | 0.80 | BACE1 (0.64) | BACE1CTSD | |
| Formic Acid SCHEMBL2283352 | 0.80 | BACE1 (0.59) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245019-B1 | 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 721/4885ADAM17 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.